Vitamin D status in acromegaly: a comparative study

Sana Mahjoubi; Hajer Kandara; Sabrine Mekni; Olfa Laajili; Sonia Nagi; Chayma Ben Amara; Ines Kamoun; Leila Ben Salem

doi:10.1530/endoabs.56.P844

P844

Prev Next

Section Contents Cite

Endocrine Abstracts (2018) 56 P844 | DOI: 10.1530/endoabs.56.P844

ECE2018 Poster Presentations: Pituitary and Neuroendocrinology Pituitary - Clinical (101 abstracts)

Vitamin D status in acromegaly: a comparative study

Sana Mahjoubi ¹ , Hajer Kandara ¹ , Sabrine Mekni ¹ , Olfa Laajili ¹ , Sonia Nagi ² , Chayma Ben Amara ¹ , Ines Kamoun ¹ & Leila Ben Salem ¹

Views

Author affiliations

¹Endocrinology and Nutrition Departement, National Nutrition Institute, Tunis, Tunisia; ²Neuroradiology Departement, National Neurology Institute, Tunis, Tunisia.

Background: The vitamin D is a pleiotropic hormone that plays a significant role on global health. However, vitamin D status in acromegaly has been poorly studied.

The aim: The aim of this study was to assess the vitamin D status in acromegaly and compare it to a control group. Then to analyse bone remodeling and density markers based on the vitamin D levels.

Methods: We conducted an evaluative cross sectional study in the Department of Endocrinology at the National Institute of Nutrition in Tunis comparing 2 groups of 25 acromegalic patients and 25 control subjects (age and sex matched).

Results: The average age was 50±14.52 years [16–52]. The sex ratio was 9/16 (36% men and 64% women). The mean duration of the acromegaly was 8.6±9.62 years. As for acromegalic repercussions patients presented with rheumatologic impacts in 80% of the cases, visual in 72%, respiratory in 68%, pituitary in 56%, metabolic in 56% and tumoral in 8%. Twenty-one subjects underwent surgical treatement, 24% were under somatostatin analogs, two patients had received radiotherapy. Acromegaly was active in 64% of the cases, controlled for 4 patients and cured for 5 (20%). The vitamin D status was similar between the acromegalic group and the control subjects: Thirteen acromegalic patients had deficiency, 9 (36%) had insufficiency and 3 patients (12%) had a normal level of vitamin D. The univariate study showed that, duration of sun exposure, exposed surface, score screening for vitamin D insufficiency, height, PTH, and GH were significantly associated with the vitamin D level in acromegalics.

Conclusion: The exploration of the vitamin D status in acromegaly should become a common practice. The management starts with the prevention of the defict, the screening and eventually a therapeutic supplementation.